How does gender-affirming hormone therapy affect QOL in transgender patients?
Publication Title
The Journal of family practice
Document Type
Article
Publication Date
12-1-2022
Keywords
washington; spokane
Abstract
There are modest effects on depression but not anxiety. Gender-affirming hormone therapy (GAHT) is associated with modest improvements in standardized scores for quality of life (QOL) and depression in adult male-to-female and female-to-male transgender people and modest improvements in depression scores in transgender adolescents, but the effect on anxiety is uncertain (strength of recommendation [SOR]: B, based on a preponderance of low-quality prospective cohort studies with inconsistent results). GAHT is associated with reduced gender dysphoria and decreased suicidality (SOR: B, based on a prospective cohort study). However, there is insufficient evidence to determine any effect on suicide completion. No studies associated GAHT with worsened QOL, depression, or anxiety scores.
Area of Special Interest
Mental Health
Specialty/Research Institute
Pharmacy
Specialty/Research Institute
Behavioral Health
